Resideo Technologies, Inc. (REZI)
Live price chart, market sentiment, and community perspectives for Resideo Technologies, Inc. (NYSE: REZI).
Live price chart, market sentiment, and community perspectives for Resideo Technologies, Inc. (NYSE: REZI).
On our desk, the reaction to REZI's Q2 print has been fundamentally schizophrenic. Management delivered an absolute beat across the board—revenue hit $1.98 billion, adjusted EBITDA climbed 19% to $249 million including $27 million in tariff refunds, and they successfully pulled off the ADI Global Distribution spin-off while paying down $900 million in debt. Yet, the stock is getting punished because the standalone fiscal outlook and Q3 revenue projections came in substantially below Wall Street's lofty expectations. If you are looking at valuation multiples on a trailing basis, it looks wildly cheap, but the market is clearly pricing in the second-half margin compression driven by rising input costs and sluggish OEM security demand.
Watching the fundamental versus alternative data divergence on REZI is fascinating. While the Products and Solutions segment just logged its 13th consecutive quarter of year-over-year gross margin expansion—hitting 43.6%—alternative tracking shows user growth holding strong at 71/100 alongside rising web traffic, yet job postings lag and the overall AI score sits at a mediocre 59/100. Investors need to weigh the immediate balance sheet cleanup from the ADI spin-off and upcoming debt repayments against the tangible near-term headwinds in housing channels and commercial end markets.
When vetting REZI for long-term portfolio allocation, my primary focus during management QandA sessions centers entirely on execution post-separation. With ADI now out of the picture as of August 3 and standalone 2026 guidance recalibrated to $2.9 billion to $2.95 billion in revenue and $605 million to $625 million in adjusted EBITDA, analysts must probe how aggressively management can protect gross margins in PandS against escalating input costs. I want to see precise operational protocols for mitigating the weaker OEM security demand signaled for the back half of the year before deploying fresh capital.
Explore plasma cleansing, somatic organ swaps, and BCI.